<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <title>Publications – Xubin Li, PhD</title>
  <meta name="viewport" content="width=device-width, initial-scale=1">

  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600&display=swap" rel="stylesheet">

  <style>
    body {
      margin: 0;
      font-family: "Inter", system-ui, -apple-system, BlinkMacSystemFont, sans-serif;
      background: #ffffff;
      color: #222;
      line-height: 1.6;
    }
    .page {
      max-width: 1000px;
      margin: 0 auto;
      padding: 24px 16px 48px;
    }
    header {
      display: flex;
      justify-content: space-between;
      align-items: center;
      padding-bottom: 12px;
      border-bottom: 1px solid #e0e0e0;
      margin-bottom: 32px;
    }
    .site-title {
      font-weight: 600;
    }
    nav a {
      margin-left: 16px;
      text-decoration: none;
      color: #555;
      font-weight: 500;
    }
    nav a:hover { color: #0f6abf; }
    nav a.active {
      color: #0f6abf;
      border-bottom: 2px solid #0f6abf;
      padding-bottom: 3px;
    }
    h1 {
      margin-top: 0;
      margin-bottom: 12px;
    }
    h2 {
      margin-top: 32px;
      margin-bottom: 8px;
      font-size: 1.25rem;
      color: #0f6abf;
    }
    h3 {
      margin-top: 18px;
      margin-bottom: 4px;
      font-size: 1.05rem;
    }
    ol {
      padding-left: 22px;
      margin-top: 6px;
    }
    li {
      margin-bottom: 6px;
    }
  </style>
</head>

<body>
  <div class="page">
    <header>
      <!-- <div class="site-title">Li Lab</div> -->
      <nav>
        <a href="index.html">Home</a>
        <a href="research.html">Research</a>
        <a href="publications.html" class="active">Publications</a>
        <a href="code.html">Code</a>
      </nav>
    </header>

    <main>
      <!-- <h1>Publications</h1> -->

      <h1>Journal Articles</h1>

      <h2>Tumor Microenvironment &amp; Lymphoma Biology</h2>
      <ol>
        <li>
          <strong>Li X</strong>, Singhal K, Deng Q, Chihara D, Russler-Germain D, Harkins RA, Henderson J, Arita K, Kizhakeyil A, Sun R, Lakra P, Hussein U, Foltz JA, Wilson A, Schmidt E, Nizamuddin I, Dinh T, Kesaraju A, Hamilton MP, Allen C, Gandhi MK, Tobin J, Jiang A, Hilton L, Scott DW, Vega F, Flowers CR, Westin JR, Griffith OL, Fehniger TA, Griffith M, Green MR. Large B cell lymphoma microenvironment archetype profiles. <strong>Cancer Cell</strong>. <strong>2025</strong> Jul 14; 43(7):1347-1364.e13.
        </li>
        <li>
          Dai Y, Kizhakeyil A, Chihara D, <strong>Li X</strong>, Liu Y, Sainz Zuniga TP, Wilson A, Henderson J, Vibe D, Petrosyants A, Jacobson C, Sarachakov A, Nomie K, Kryukov K, Bagaev A, Chauhan A, Westin JR, Flowers CR, Vega F, Wang L, Green MR. Multi-modal spatial characterization of tumor immune microenvironments identifies targetable inflammatory niches in diffuse large B cell lymphoma. <strong>Nature Genetics</strong>. <strong>2025</strong>. doi:10.1038/s41588-025-02353-5.
        </li>
        <li>
          Deng Q, Lakra P, Gou P, Yang H, Meydan C, Teater M, Chin C, Zhang W, Dinh T, Hussein U, <strong>Li X</strong>, Rojas E, Liu W, Reville PK, Kizhakeyil A, Barisic D, Parsons S, Wilson A, Henderson J, Scull B, Gurumurthy C, Vega F, Chadburn A, Cuglievan B, El-Mallawany NK, Allen C, Mason C, Melnick A, Green MR. SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. <strong>Cancer Cell</strong>. <strong>2024</strong> Apr 08; 42(4):605-622.e11.
        </li>
        <li>
          Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, <strong>Li X</strong>, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, Wang L, Green MR. Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression. <strong>Blood Cancer Discovery</strong>. <strong>2022</strong> Sep 06; 3(5):428-443.
        </li>
      </ol>

      <h2>CAR T Cell Therapy</h2>
      <ol start="5">
        <li>
          <strong>Li X</strong>, Henderson J, Gordon MJ, Sheikh IN, Nastoupil L, Westin JR, Flowers CR, Ahmed S, Wang L, Neelapu SS, Strati P, Deng Q, Green M. A single-cell atlas of CD19 chimeric antigen receptor T cells. <strong>Cancer Cell</strong>. <strong>2023</strong> Nov 13; 41(11):1835-1837.
        </li>
        <li>
          Strati P<sup>1</sup>, <strong>Li X<sup>1</sup></strong>, Deng Q<sup>1</sup>, Marques-Piubelli ML, Henderson J, Watson G, Deaton FL, Cain JT, Yang H, Ravanmehr V, Fayad LE, Iyer SP, Nastoupil L, Hagemeister FB, Parra ER, Saini N, Takahashi K, Fowler N, Westin JR, Steiner RE, Nair R, Flowers CR, Wang L, Ahmed S, Al-Atrash G, Vega F, Neelapu SS, Green M. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. <strong>Cell Reports Medicine</strong>. <strong>2023</strong> Aug 15; 4(8):101158. (1 = Co-first authors)
        </li>
        <li>
          Strati P, Jallouk AP, Deng Q, <strong>Li X</strong>, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Iyer S, Horowitz S, Nastoupil L, Nair R, Hassan A, Daoud T, Hawkins MC, Rodriguez MA, Shpall E, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green M. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma. <strong>Blood Advances</strong>. <strong>2023</strong> Jan 01; 7(21):6785-6789.
        </li>
        <li>
          Reville PK, Sheikh IN, Choi A, Dai E, Henderson J, <strong>Li X</strong>, Rojas E, Le C, Okwuchi C, Devonish M, Carrio R, Pate N, Malley K, Bangari D, Givigan JA, Shi C, Liu B, Byers T, Westin J, Ahmed S, Fowler N, Fayad L, Lee HJ, Nastoupil L, Sassoon I, Cucchetti M, Wang R, Agarwal M, Abbadessa G, Meng R, Meibalan E, Powers L, Cao J, Ying X, Balko K, Yu Q, Jiao J, Cortez-Retamozo V, Sidhu S, Shaffer D, Neelapu S, Wang L, <strong>Li X</strong>, Green M. CD8 T-cell dysfunction is linked with CAR T-cell failure and can be mitigated by a non-alpha IL-2 agonist, pegenzileukin. <strong>bioRxiv</strong>. <strong>2023</strong> Aug 28.
        </li>
      </ol>

      <h2>Bioinformatics &amp; Pan-Cancer Genomics</h2>
      <ol start="9">
        <li>
          <strong>Li X</strong>, Dowling EK, Yan G, Dereli Korkut Z, Bozorgui B, Imanirad P, Elnaggar JH, Luna A, Menter DG, Pilie PG, Yap TA, Kopetz S, Sander C, Korkut A. Precision Combination Therapies Based on Recurrent Oncogenic Coalterations. <strong>Cancer Discovery</strong>. <strong>2022</strong> Jun 01; 12(6):1542-1559.
        </li>
        <li>
          <strong>Li X</strong>, Nguyen J, Korkut A. Recurrent composite markers of cell types and states. <strong>bioRxiv</strong>. <strong>2023</strong> Jul 19.
        </li>
        <li>
          Vishnoi M, Dereli Z, Yin Z, Kong EK, Kinali M, Thapa K, Babur O, Yun K, Abdelfattah N, <strong>Li X</strong>, Bozorgui B, Rostomily RC, Korkut A. A prognostic matrix code defines functional glioblastoma phenotypes and niches. <strong>bioRxiv</strong>. <strong>2023</strong> Jun 8.
        </li>
        <li>
          Yan G, Luna A, Wang H, Bozorgui B, <strong>Li X</strong>, Sanchez M, Dereli Korkut Z, Kahraman N, Kara G, Chen X, Zheng C, McGrail DJ, Sahni N, Lu Y, Babur Ö, Cokol M, Lim B, Ozpolat B, Sander C, Mills GB, Korkut A. BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer. <strong>Cell Reports</strong>. <strong>2022</strong> Sep 13; 40(11).
        </li>
        <li>
          Wang H, Luna A, Yan G, <strong>Li X</strong>, Babur O, Mills GB, Sander C, Korkut A. Targeting Adaptation to Cancer Treatment by Drug Combinations. <strong>bioRxiv</strong>. <strong>2021</strong> Apr 14.
        </li>
        <li>
          Donehower LA, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, <strong>Li X</strong>, Babur O, Hsu TK, Lichtarge O, Weinstein JN, Akbani R, Wheeler DA. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. <strong>Cell Reports</strong>. <strong>2019</strong> Jul 30; 28(5):1370-1384.e5.
        </li>
        <li>
          Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, <strong>Li X</strong>, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L, Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-beta Superfamily. <strong>Cell Systems</strong>. <strong>2018</strong> Oct 24; 7(4):422-437.e7.
        </li>
        <li>
          Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, <strong>Li X</strong>, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N, Weinstein JN, Mills GB, Levine DA, Akbani R. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. <strong>Cancer Cell</strong>. <strong>2018</strong> Apr 09; 33(4):690-705.e9.
        </li>
      </ol>

      <h2>Biophysics</h2>
      <ol start="17">
        <li>
          <strong>Li X</strong>, Qu T, Zheng L, Yang W. A Gaussian Kernel Monte Carlo Resampling Method to Construct Smooth Free Energy Surface from Discrete Simulation Data. <strong>Journal of Chemical Physics</strong>. <strong>2025</strong> Jun 21; 162(23):234101.
        </li>
        <li>
          Lu C<sup>1</sup>, <strong>Li X<sup>1</sup></strong>, Wu D, Zheng L, Yang W. Predictive Sampling of Rare Conformational Events in Aqueous Solution: Designing a Generalized Orthogonal Space Tempering Method. <strong>Journal of Chemical Theory and Computation</strong>. <strong>2016</strong> Jan 12; 12(1):41-52. (1 = Co-first authors)
        </li>
        <li>
          <strong>Li X</strong>, Lv C, Corbett KM, Zheng L, Wu D, Yang W. Free energy landscape of a minimalist salt bridge model. <strong>Protein Science</strong>. <strong>2016</strong> Jan; 25(1):270-6.
        </li>
      </ol>

      <h1>Conference Abstracts</h1>
      <ol start="20">
        <li>
          Russler-Germain DA, <strong>Li X</strong>, Singhal K, Deng Q, Chihara D, Hussein U, Foltz JA, Henderson J, Wilson A, Tobin J, Gandhi MK, Schmidt E, Nizamuddin I, Dinh T, Sun R, Kesaraju A, Hilton L, Scott DW, Vega F, Flowers CR, Westin JR, Griffith OL, Fehniger TA, Griffith M, Green MR. Large B-cell lymphoma microenvironment archetype profiles (LymphoMAPs) identify subgroups with greatest benefit from CD19 CAR T-cell therapy. <strong>Hematological Oncology</strong>. <strong>2025</strong> Jun 16.
        </li>
        <li>
          <strong>Li X</strong>, Singhal K, Deng Q, Chihara D, Russler-Germain DA, Hussein U, Foltz JA, Henderson J, Wilson A, Schmidt E, Nizamuddin IA, Dinh T, Sun R, Kesaraju A, Hilton LK, Scott DW, Vega F, Flowers CR, Griffith O, Fehniger TA, Griffith M, Green MR. Comprehensive Characterization and Validation of the Tumor Microenvironment in Patients with Relapsed/Refractory Large B-Cell Lymphoma Identifies Subgroups with Greatest Benefit from CD19 CAR T-Cell Therapy. <strong>Blood</strong>. <strong>2024</strong> Nov 15; 144(Suppl 1):643.
        </li>
        <li>
          <strong>Li X</strong>, Singhal K, Deng Q, Chihara D, Russler-Germain D, Hussein U, Foltz JA, Henderson J, Wilson A, Schmidt E, Nizamuddin I, Dinh T, Sun R, Vega F, Flowers C, Griffith O, Fehniger T, Griffith M, Green MR. Comprehensive characterization of the non-tumor microenvironment of relapsed/refractory large B-cell lymphoma identifies patients with greatest benefit from CD19 CAR T-cell therapy. <strong>Blood Cancer Discovery</strong>. <strong>2024</strong> Mar; 5(3_Suppl):PR06.
        </li>
        <li>
          <strong>Li X</strong>, Deng Q, Henderson J, Watson G, Deaton L, Cain T, Fayad L, Padmanabhan Iyer S, Hagemeister FB, Nastoupil LJ, Fowler NH, Westin J, Steiner R, Nair R, Ahmed S, Alatrash G, Neelapu SS, Strati P, Green MR. Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy. <strong>Blood</strong>. <strong>2022</strong> Nov 5; 140(Suppl 1):4502–4503.
        </li>
        <li>
          Strati P, <strong>Li X</strong>, Deng Q, Feng L, Sun R, Jallouk A, Adkins S, Cain T, Johncy S, Steiner RE, Ahmed S, Chihara D, Fayad L, Padmanabhan Iyer S, Horowitz SB, Nehlsen R, Nastoupil LJ, Nair R, Hassan A, Daoud T, Hawkins M, Samaniego F, Rodriguez MA, Shpall EJ, Kebriaei P, Flowers CR, Hong D, Westin J, Neelapu SS, Green MR. Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-Cell Lymphoma. <strong>Blood</strong>. <strong>2022</strong> Nov 5; 140(Suppl 1):7493-7495.
        </li>
      </ol>

    </main>
  </div>
</body>
</html>
